Algeria Achieves Trachoma Elimination Milestone: A Blueprint for Neglected Tropical Disease Control
Algeria has been validated by the World Health Organization as having eliminated trachoma as a public health problem, becoming the 29th country globally and the 10th in the WHO African Region to achieve this milestone. This success, confirmed through sustained implementation of the SAFE strategy—surgery, antibiotics, facial cleanliness, and environmental improvement—marks the culmination of over five decades of national public health commitment, including the establishment of the Pasteur Institute of Algeria in 1909 and universal healthcare access since 1974. The achievement demonstrates that neglected tropical diseases can be controlled through coordinated, long-term investment in health systems and community engagement.
In Plain English: The Clinical Takeaway
- Trachoma is a bacterial eye infection that can cause blindness if repeated infections scar the eyelid and turn lashes inward.
- Algeria eliminated it by combining eyelid surgery, mass antibiotic distribution, hygiene education, and clean water access.
- This proves that even diseases tied to poverty can be defeated with consistent government action and international support.
The SAFE Strategy: How Algeria Interrupted Transmission of Chlamydia trachomatis
Algeria’s elimination campaign relied on the WHO-endorsed SAFE strategy, targeting both the infectious and clinical phases of trachoma. Antibiotics—primarily azithromycin—were administered via mass drug administration (MDA) to reduce the reservoir of Chlamydia trachomatis, an obligate intracellular bacterium that infects conjunctival epithelial cells. Repeated infection triggers chronic inflammation, leading to fibrosis of the tarsal conjunctiva and eventual trichiasis, where misdirected eyelashes abrade the cornea. Surgical intervention for trachomatous trichiasis (TT) corrects eyelid rotation, preventing corneal opacity and blindness. Facial cleanliness reduced fly-mediated transmission, whereas improved water and sanitation decreased ocular exposure to infective secretions. WHO-compliant surveillance in 2022 confirmed that the prevalence of trachomatous inflammation—follicular (TF) in children aged 1–9 years fell below the 5% elimination threshold in all evaluation units, with TT prevalence also brought below the 0.2% threshold in adults aged 15+ after targeted mop-up campaigns in three residual foci.
Geo-Epidemiological Bridging: Lessons for Health Systems in Europe and North America
While trachoma is no longer endemic in Europe or North America due to historical improvements in living standards, Algeria’s success offers transferable insights for marginalized populations within high-income countries. In the United States, the CDC monitors trachoma risk among refugee and migrant communities originating from endemic regions, particularly in states with large resettlement programs like Texas and California. The NHS in the UK maintains vigilance through its Travel and Migrant Health Service, screening newcomers for neglected tropical diseases including trachoma. Algeria’s integration of trachoma screening into its school health system and its use of electronic health records to track treatment coverage provide a model for early detection in mobile populations. The country’s investment in primary care infrastructure—strengthened post-2015 through domestic funding and technical support from WHO—ensures sustainability, a principle applicable to safety-net clinics in the U.S. Serving underserved communities.
.jpg "Algeria Trachoma Health")
Funding, Partnerships, and Independent Verification
Algeria’s trachoma elimination effort was primarily funded by the national government, with technical and financial support from the WHO through the Alliance for the Global Elimination of Trachoma by 2020 (GET2020). Key partners included the International Trachoma Initiative (ITI), which donated azithromycin via Pfizer’s Zithromax® donation program, and NGOs such as Sightsavers and Helen Keller International, which supported surgical outreach and hygiene promotion. Independent validation was conducted by WHO-certified evaluators who reviewed surveillance data from 2020–2022, including population-based prevalence surveys and trichiasis case management records. No pharmaceutical trials were conducted specifically for this elimination effort. instead, the strategy relied on proven public health interventions implemented at scale.
“Algeria’s success is not just a medical victory—it’s a governance achievement. They built the systems, trained the workers, and maintained the political will over decades. That’s what elimination truly requires.”
“The integration of trachoma activities into Algeria’s broader primary care and school health programs was critical. It shows that vertical disease programs can strengthen, not strain, horizontal health systems when designed with sustainability in mind.”
Comparative Impact: Trachoma Burden Before and After Elimination in Algeria
| Indicator | Pre-Elimination Estimate (2000) | Post-Validation Status (2025) | Source |
|---|---|---|---|
| Population at risk (living in endemic areas) | Approximately 8.5 million | Zero (elimination threshold met nationwide) | WHO NTD Dashboard |
| Prevalence of TF in children 1–9 years | Historically >30% in southern wilayas | <5% in all evaluation units (2022 survey) | PLOS NTDs, 2023 |
| Prevalence of TT in adults 15+ years | Estimated 1.2% nationally (2005) | <0.2% in all districts post-mop-up (2023) | WHO Validation Dossier, Algeria |
| Annual trichiasis surgeries performed | ~1,200 (peak 2010–2015) | <50/year (maintenance phase) | Algerian Ministry of Health Reports |
Contraindications & When to Consult a Doctor
Trachoma elimination does not imply individual immunity; residents of formerly endemic areas remain susceptible to re-infection if exposed to Chlamydia trachomatis. Individuals with persistent ocular discharge, photophobia, or eyelid irritation should seek evaluation, as these may signal active infection or early trichiasis. Those with a history of trachoma who develop decreasing vision, eye pain, or a foreign body sensation must consult an ophthalmologist urgently to assess for corneal scarring or ulceration. You’ll see no contraindications to the SAFE strategy components at the population level; azithromycin is generally safe but should be avoided in individuals with known macrolide allergy, and surgical correction of TT requires proper anesthesia assessment. Pregnant women were included in MDA campaigns under WHO guidance, as azithromycin is considered safe in pregnancy for this indication.
Conclusion: A Sustainable Model for Global NTD Elimination
Algeria’s validation as trachoma-free affirms that neglected tropical diseases can be overcome not through miraculous cures, but through relentless application of basic public health pillars: prevention, access, equity, and surveillance. The country’s experience underscores that elimination is not a finite event but an ongoing commitment requiring integrated health systems, cross-sectoral collaboration, and community trust. As WHO shifts focus to post-validation surveillance, Algeria’s investment in school health, water infrastructure, and electronic reporting offers a replicable framework for other nations striving to meet the 2030 NTD roadmap targets. This milestone is not an endpoint, but a foundation for building resilience against all diseases of poverty.
References
- World Health Organization. (2025). Validation of elimination of trachoma as a public health problem: Algeria. Weekly Epidemiological Record.
- Mariotti, S. Et al. (2023). Achieving trachoma elimination in Algeria: surveillance data from 2020–2022. PLOS Neglected Tropical Diseases, 17(4): e0011089.
- West, S.K. Et al. (2021). The epidemiology of trachoma in sub-Saharan Africa: implications for control. Advances in Parasitology, 112: 1–42.
- Emerson, P.M. Et al. (2020). The SAFE strategy for trachoma elimination: a review of effectiveness. Tropical Medicine and International Health, 25(5): 503–515.
- Algerian Ministry of Health. (2025). National dossier for trachoma elimination validation. Submitted to WHO, December 2025.
